PMID- 33038982
OWN - NLM
STAT- MEDLINE
DCOM- 20211007
LR  - 20211007
IS  - 1532-1924 (Electronic)
IS  - 1521-6926 (Print)
IS  - 1521-6926 (Linking)
VI  - 33
IP  - 3
DP  - 2020 Sep
TI  - Molecular markers in ALL: Clinical implications.
PG  - 101193
LID - S1521-6926(20)30054-2 [pii]
LID - 10.1016/j.beha.2020.101193 [doi]
AB  - Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and 
      remains a main cause of death in children despite recent improvements in cure 
      rates. In the past decade, development of massively parallel sequencing has 
      enabled large scale genome profiling studies of ALL, which not only led to 
      identification of new subtypes in both B-cell precursor ALL (BCP-ALL) and T-cell 
      ALL (T-ALL), but has also identified potential new therapeutic approaches to 
      target vulnerabilities of many subtypes. Several of these approaches have been 
      validated in preclinical models and are now being formally evaluated in 
      prospective clinical trials. In this review, we provide an overview of the recent 
      advances in our knowledge of genomic bases of BCP-ALL, T-ALL, and relapsed ALL, 
      and discuss their clinical implications.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Kimura, Shunsuke
AU  - Kimura S
AD  - Department of Pathology, Hematological Malignancies Program, St. Jude Children's 
      Research Hospital, 262 Danny Thomas Place, Mail Stop 342, Memphis, 38105, TN, 
      USA.
FAU - Mullighan, Charles G
AU  - Mullighan CG
AD  - Department of Pathology, Hematological Malignancies Program, St. Jude Children's 
      Research Hospital, 262 Danny Thomas Place, Mail Stop 342, Memphis, 38105, TN, 
      USA. Electronic address: charles.mullighan@stjude.org.
LA  - eng
GR  - P30 CA021765/CA/NCI NIH HHS/United States
GR  - P50 GM115279/GM/NIGMS NIH HHS/United States
GR  - R35 CA197695/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200607
PL  - Netherlands
TA  - Best Pract Res Clin Haematol
JT  - Best practice & research. Clinical haematology
JID - 101120659
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - *Biomarkers, Tumor/genetics/metabolism
MH  - Clinical Trials as Topic
MH  - Humans
MH  - *Precursor B-Cell Lymphoblastic 
      Leukemia-Lymphoma/classification/genetics/metabolism/therapy
MH  - *Precursor T-Cell Lymphoblastic 
      Leukemia-Lymphoma/classification/genetics/metabolism/therapy
PMC - PMC7548398
MID - NIHMS1606307
OTO - NOTNLM
OT  - ALL
OT  - Acute lymphoblastic leukemia
OT  - B-ALL
OT  - DUX4
OT  - ETP
OT  - ETV6-RUNX1
OT  - Hyperdiploid
OT  - Hypodiploid
OT  - IKZF1
OT  - KMT2A
OT  - MEF2D
OT  - PAX5
OT  - Ph-like
OT  - Relapse
OT  - T-ALL
OT  - TAL1
OT  - TCF3
OT  - TLX1/3
OT  - ZNF384
EDAT- 2020/10/12 06:00
MHDA- 2021/10/08 06:00
PMCR- 2021/09/01
CRDT- 2020/10/11 20:19
PHST- 2020/03/09 00:00 [received]
PHST- 2020/04/28 00:00 [revised]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/10/11 20:19 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/10/08 06:00 [medline]
PHST- 2021/09/01 00:00 [pmc-release]
AID - S1521-6926(20)30054-2 [pii]
AID - 10.1016/j.beha.2020.101193 [doi]
PST - ppublish
SO  - Best Pract Res Clin Haematol. 2020 Sep;33(3):101193. doi: 
      10.1016/j.beha.2020.101193. Epub 2020 Jun 7.